Consolidated gross sales revenue for the quarter elevated by 8.6% year-on-year (YoY) to Rs 14,405 billion. |Photograph courtesy: FRANCIS MASCARENHAS
Solar Pharmaceutical Industries Ltd. reported a 2.6% enhance in consolidated web revenue to Rs 3,118 crore for the second quarter ended September 30, 2025.
Consolidated gross sales revenue for the quarter elevated by 8.6% year-on-year (YoY) to Rs 14,405 billion.
Managing Director Kirti Ganolkar stated, “India, rising markets and the remainder of the world drove our development within the quarter. Gross sales of revolutionary medicines within the US exceeded generic medicines for the primary time within the quarter.”
“We stay targeted on increasing our portfolio whereas strengthening our inside expertise pool and execution capabilities,” he added.
Gross sales of formulations in India rose 11% to Rs 4,735 crore. Pharmaceutical gross sales in India accounted for 32.9% of whole consolidated gross sales for the quarter.
Solar Pharma’s market share elevated from 8% to eight.3%.
US formulations gross sales had been $496 million, a lower of 4.1%. Declines within the generic drug enterprise had been offset by development in revolutionary medicines. Based on the corporate, gross sales in america accounted for roughly 30.1% of consolidated gross sales.
Within the second quarter of 2026, Rising Markets Formulations gross sales had been $325 million, a rise of 10.9% and represented 19.7% of whole consolidated gross sales.
Remainder of World (RoW) market formulation gross sales for the quarter had been $234 million, a rise of 17.7% and represented 14.2% of whole consolidated gross sales for the quarter.
